| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_676b80da7ac92b84e447a83fb1630ae1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_77fb1c5cf59976673a372df619f75556
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_593e8c814209bf6becf0b19b368ae574 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T428-2982 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6907
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6933
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-1824
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0414 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 |
| filingDate |
2009-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1136e7f6558eabaa876e656f12a7edde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2be7e59cd95c945151db2fdf66c3e7e |
| publicationDate |
2009-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009139939-A2 |
| titleOfInvention |
Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents |
| abstract |
The presently disclosed subject matter provides nanoscale coordination polymers for use as anticancer agents and as dual anticancer/imaging agents. The nanoscale coordination polymers can comprise a plurality of platinum metal complexes; nonplatinum anticancer drug bridging ligands complexed to multiple metal centers; or combinations thereof. The nanoscale coordination polymers can be targeted for delivery to cancer cells. They can also comprise stabilizing agents to allow for controlled and/or sustained release of anticancer agents in vivo. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105214089-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10596116-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11246877-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11358133-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108559100-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013112823-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206871-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011133925-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102584900-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101787053-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112870355-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111194232-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111194232-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3494974-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2371926-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019218275-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9693957-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108559100-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110384703-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112870355-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10780045-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2729180-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011133925-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10806694-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013009701-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8766315-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2971942-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105214089-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10517822-B2 |
| priorityDate |
2008-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |